Your browser doesn't support javascript.
loading
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase.
Heudobler, Daniel; Luke, Florian; Hahn, Joachim; Grube, Matthias; Schlosser, Pavla; Kremers, Stephan; Sudhoff, Thomas; Westermann, Jorg; Hutter-Kronke, Marie Luise; Schlenk, Richard F; Weber, Daniela; Paschka, Peter; Zeman, Florian; Dohner, Hartmut; Herr, Wolfgang; Reichle, Albrecht; Thomas, Simone.
Afiliação
  • Heudobler D; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Bavarian Center for Cancer Research, University Hospital Regensburg, Regensburg. daniel.heudobler@ukr.de.
  • Luke F; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg.
  • Hahn J; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology.
  • Grube M; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology.
  • Schlosser P; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology.
  • Kremers S; Caritaskrankenhaus Lebach, Department of Hematology/Oncology.
  • Sudhoff T; Klinikum Passau, Department Hematology and Oncology.
  • Westermann J; Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin.
  • Hutter-Kronke ML; Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin, Germany; University Hospital Ulm, Department of Internal Medicine III.
  • Schlenk RF; National Center of Tumor Diseases Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany; Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg.
  • Weber D; University Hospital Ulm, Department of Internal Medicine III.
  • Paschka P; University Hospital Ulm, Department of Internal Medicine III.
  • Zeman F; Center for Clinical Studies, University Hospital Regensburg, Regensburg.
  • Dohner H; University Hospital Ulm, Department of Internal Medicine III.
  • Herr W; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology.
  • Reichle A; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology.
  • Thomas S; University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Leibniz Institute for Immunotherapy, Division of Genetic Immunotherapy, Regensburg.
Haematologica ; 109(4): 1274-1278, 2024 Apr 01.
Article em En | MEDLINE | ID: mdl-37881883
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article